BR9807828A - Compositions and method for testosterone supplementation in women with symptoms of testosterone deficiency - Google Patents

Compositions and method for testosterone supplementation in women with symptoms of testosterone deficiency

Info

Publication number
BR9807828A
BR9807828A BR9807828-3A BR9807828A BR9807828A BR 9807828 A BR9807828 A BR 9807828A BR 9807828 A BR9807828 A BR 9807828A BR 9807828 A BR9807828 A BR 9807828A
Authority
BR
Brazil
Prior art keywords
testosterone
women
compositions
supplementation
symptoms
Prior art date
Application number
BR9807828-3A
Other languages
Portuguese (pt)
Inventor
Susan Rako
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of BR9807828A publication Critical patent/BR9807828A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

Patente de Invenção: <B>"COMPOSIçõES E MéTODO PARA A SUPLEMENTAçãO DE TESTOSTERONA EM MULHERES COM SINTOMAS DE DEFICIêNCIA DE TESTOSTERONA"<D>. A presente invenção proporciona composições para prover esteróides androgênicos, tais como a testosterona, em quantidades eficazes a mulheres que estão necessitando de suplementação de esteróides androgênico.Invention Patent: <B> "COMPOSITIONS AND METHOD FOR THE SUPPLEMENTATION OF TESTOSTERONE IN WOMEN WITH TESTOSTERONE DEFICIENCY SYMPTOMS" <D>. The present invention provides compositions for providing androgenic steroids, such as testosterone, in effective amounts to women who are in need of androgenic steroid supplementation.

BR9807828-3A 1997-02-07 1998-02-05 Compositions and method for testosterone supplementation in women with symptoms of testosterone deficiency BR9807828A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3747397P 1997-02-07 1997-02-07
US3971797P 1997-02-12 1997-02-12
US4664297P 1997-05-16 1997-05-16
PCT/US1998/002089 WO1998034621A1 (en) 1997-02-07 1998-02-05 Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency

Publications (1)

Publication Number Publication Date
BR9807828A true BR9807828A (en) 2000-03-08

Family

ID=27365214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807828-3A BR9807828A (en) 1997-02-07 1998-02-05 Compositions and method for testosterone supplementation in women with symptoms of testosterone deficiency

Country Status (8)

Country Link
EP (1) EP0998289A1 (en)
JP (1) JP2001512440A (en)
KR (1) KR20000070757A (en)
CN (1) CN1250373A (en)
AU (1) AU6265998A (en)
BR (1) BR9807828A (en)
CA (1) CA2280033A1 (en)
WO (1) WO1998034621A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE460939T1 (en) * 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN
MXPA03001859A (en) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Method of increasing testosterone and related steroid concentrations in women.
KR20050074896A (en) * 2002-03-15 2005-07-19 유니메드 파마슈티칼스, 인크. Androgen pharmaceutical composition and method for treating depression
IL163981A0 (en) * 2002-03-15 2005-12-18 Unimed Pharmaceuticals Inc Androgen pharmaceutical composition and method fortreating depression
WO2004043429A1 (en) * 2002-11-12 2004-05-27 Pharmacia & Upjohn Company Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, and at least one agent selected from an estrogen and an anti-muscarinic
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
KR20080009201A (en) 2005-04-15 2008-01-25 클라루스 쎄러퓨틱스, 아이엔씨. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20140274985A1 (en) * 2013-03-15 2014-09-18 Raman Malhotra Systemic administration of androgen in treating dry eye syndrome
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CN106922128B (en) 2014-08-28 2021-04-02 得克萨斯州大学系统董事会 Testosterone formulations and methods of treatment
CA3016542A1 (en) * 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
CN114728013A (en) * 2019-09-23 2022-07-08 斯坦福大学托管董事会 Methods of treating prolonged pregnancy and complications of menstruation or pregnancy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols

Also Published As

Publication number Publication date
JP2001512440A (en) 2001-08-21
CA2280033A1 (en) 1998-08-13
KR20000070757A (en) 2000-11-25
CN1250373A (en) 2000-04-12
WO1998034621A1 (en) 1998-08-13
EP0998289A1 (en) 2000-05-10
AU6265998A (en) 1998-08-26

Similar Documents

Publication Publication Date Title
BR9807828A (en) Compositions and method for testosterone supplementation in women with symptoms of testosterone deficiency
ES2155874T3 (en) COSMETIC COMPOSITIONS CONTAINING BETULIN ACID.
MY126960A (en) Administration of non-oral androgenic steroids to women
ATE460939T1 (en) METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN
CA2419573A1 (en) Method of increasing testosterone and related steroid concentrations in women
PT841898E (en) TYPICAL COMPOSITIONS THAT PROVIDE BETTER SKIN SENSATION
BR9916060A (en) Pentacyclic triterpenes
PT748190E (en) METHODS AND FORMULATIONS FOR USE IN THE TREATMENT OF BENIGN GYNECOLOGICAL DISTURBLES
TR200003513T2 (en) Pirolo [2,3d] Pyrimidine compositions and uses
IL114294A0 (en) Sterol derivatives
DE60040753D1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL FAULT EXPOSURES
BRPI0411319A (en) therapeutically active compounds and their use
UA35589C2 (en) INHIBITORS OF TESTOSTERONE 5-&lt;font face=&#34;Symbol&#34;&gt;a&lt;/font&gt;-REDUCTASE activity, pharmaceutical composition and a method for inhibiting activity of testosterone 5-&lt;font face=&#34;Symbol&#34;&gt;a&lt;/font&gt;-REDUCTASE
BR0113625A (en) Exemestane as a chemoprevention agent
CL2004000026A1 (en) USE OF A COMPOSITION THAT INCLUDES 0 TO AROUND 29% OF CIS-CLOMIFEN AND AROUND 100 TO AROUND 71% OF TRANS-CLOMIFENE TO PREPARE A USEFUL DRUG TO INCREASE THE LEVELS OF TESTOSTERONE IN SERUM IN A MALE MALE.
BR9906998A (en) Method and compositions to reduce dermatological aging and to reduce bruises
PT1421099E (en) 17-ALPHA, 21-DIHYDROXYGENEAN ESTERS AS ANTI-ANDROGENIC AGENTS
ES2166549T3 (en) PREPARATION PROCEDURE FOR 17-ESTERES OF 9ALFA, 21-DIHALO-PREGNAN-11BETA, 17ALFADIOL-20-ONAS.
RS90504A (en) C-17 spirolactonization and 6,7 oxidation of steroids
BR0308584A (en) Androgenic pharmaceutical composition and method for treating depression
ES2124064T3 (en) COMPOUNDS AND COMPOSITIONS WITH NON-BASIC NITROGENATED SIDE CHAINS.
EE200300305A (en) Gel composition and transcrotic use of the composition for the treatment of hypogonadism
DE69535267D1 (en) USE FOR THE ADMINISTRATION OF ESTROGEN
TW371630B (en) Deodorizer
ATE419855T1 (en) THERAPY FOR HORMONE REPLACEMENT AND DEPRESSION CONTAINING DIENOGEST

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired